Biohaven Ltd. Income Taxes Receivable, Current
Biohaven Ltd. (BHVN) had Income Taxes Receivable, Current of $2.60 million as of 2024-12-31, per its 10-K filed 2025-03-03.
Financial Statements › Notes
us-gaap:IncomeTaxesReceivable · last filed 2025-03-03
- 2024-12-31: Income Taxes Receivable, Current $2.60M.
- 2024-09-30: Income Taxes Receivable, Current $5.32M.
- 2024-06-30: Income Taxes Receivable, Current $7.52M.
- 2024-03-31: Income Taxes Receivable, Current $8.43M.
| Period end | Income Taxes Receivable, Current |
|---|---|
| 2024-12-31 | $2.60M 10-K · filed 2025-03-03 |
| 2024-09-30 | $5.32M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $7.52M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $8.43M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $13.25M 10-K · filed 2025-03-03 |
| 2023-09-30 | $13.07M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $8.66M 10-Q · filed 2023-07-31 |
| 2023-03-31 | $43.83M 10-Q · filed 2023-05-12 |
| 2022-12-31 | $46.14M 10-K · filed 2024-02-29 |
| 2022-09-30 | $11.34M 10-Q · filed 2022-11-09 |
| 2021-12-31 | $9.91M 10-K · filed 2023-03-23 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |